Chemotherapy and anti-CD20 monoclonal antibody impact on SARS-CoV-2 nucleic acid amplification tests in hematologic malignancies: a retrospective study.

ABSTRACT:

Background

Patients with hematologic malignancies may experience prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to evaluate risk factors for persistent SARS-CoV-2 infection in patients with hematologic malignancies based on nucleic acid amplification test (NAAT) results. Patients with SARS-CoV-2 NAAT positivity lasting ≥ 8 weeks (persistent NAAT-positive group) were compared with those who became NAAT-negative within 8 weeks (non-persistent NAAT-positive group).

Methods

We examined patients with COVID-19 and hematologic malignancies between April 2021 and January 2023 at Tenri Hospital in Japan, examining hematologic malignancy type, chemotherapy regimens, and laboratory data.

Results

NAAT results at 8 weeks were ava

SUBMITTER: Kinoshita K 

PROVIDER: S-EPMC12542058 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature